AviadoBio Secures $20M Funding to Revolutionize Gene Therapy for Neurodegenerative Diseases

AviadoBio, a pioneering company dedicated to revolutionizing treatments for frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), is thrilled to announce that it has successfully raised $20 million in funding. This significant financial boost will empower the company to accelerate its groundbreaking research and development initiatives, with a keen focus on unfolding new therapeutic options for individuals living with these challenging neurodegenerative conditions. At AviadoBio, we are committed to translating cutting-edge scientific discoveries into precision therapies that can deliver real, life-altering benefits to patients and their families. Our proprietary gene therapy platforms, paired with innovative delivery technology, are designed with a neuroanatomy-led approach to optimize drug delivery directly to the brain, maximizing therapeutic impact while minimizing side effects. This investment comes on the heels of our collaboration with esteemed institutions, including King’s College London and the UK Dementia Research Institute, marking a pivotal step in our mission to tackle the complexity of neurodegeneration. By leveraging this funding, we aim to scale our research capabilities, enhance our workforce, and accelerate clinical trials that will bring us closer to potential cures. We are grateful for the support and confidence of our investors as we embark on this transformative journey to improve the lives of those affected by FTD and ALS, and we remain steadfast in our resolve to be at the forefront of medical innovation in the fight against these neurodegenerative diseases.